D'Agostino H R, Barnett C A, Zielinski X J, Gordan G S
Department of Radiology, Veterans Administration Medical Center, Martinez, California.
Clin Orthop Relat Res. 1988 May(230):223-8.
To ascertain whether salmon calcitonin, usually given parenterally, could control active Paget's disease when given by nasal insufflation, intranasal salmon calcitonin (INSC) was given to nine men with Paget's disease whose serum alkaline phosphatase (SAP) levels were elevated twofold or more. Treatment with 100, 200, and 400 IU/day for three to nine months was well tolerated. SAP fell 31%-51% in three patients and more than 20% in two others. Three of four men who had previously received salmon calcitonin (SC) by injection had no response of SAP but had a rise in antibodies to SC. INSC is mildly effective and more convenient than parenteral SC, but dose response and efficacy relative to parenteral SC have not been established, thereby raising questions of cost-effectiveness.
为确定通常经肠胃外给药的鲑鱼降钙素经鼻内给药时能否控制活动期佩吉特病，对9名血清碱性磷酸酶（SAP）水平升高两倍或更多的佩吉特病男性患者给予鼻内鲑鱼降钙素（INSC）。给予100、200和400 IU/天治疗三至九个月，耐受性良好。3例患者的SAP下降了31%-51%，另外2例下降超过20%。4名先前接受过注射用鲑鱼降钙素（SC）的男性中，有3名患者的SAP无反应，但抗SC抗体升高。INSC有轻度疗效，且比肠胃外给药的SC更方便，但相对于肠胃外给药的SC，其剂量反应和疗效尚未确定，因此引发了成本效益问题。
